References
- Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K., Cleary M. L., Delsol G., De Wolf‐Peeters C., Falini B., Gatter K. C. A revised European‐American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
- Siegert W., Nerl C., Agthe A., Engelhard M., Brittinger G., Tiemann M., Lennert K., Huhn D., The Kiel Lymphoma Study Group. Angioimmunoblastic lymphadenopathy (A1LD)‐type T‐cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. Annals of Oncology 1995; 6: 659–664
- Sallah S., Gagnon G. A. Angioimmunoblastic lymphadenopathy with dysproteinemia: emphasis onpathogene‐sis and treatment. Acta Haematologica 1998; 99: 57–64
- Siegert W., Nerl C., Meuthen I., Zahn T., Brack N., Lennert K., Huhn D. Recombinant human inter‐feron‐alpha in the treatment of angioimmunoblastic lymphadenopathy: results in 12 patients. Leukemia 1991; 5: 892–895
- Murayama T., Imoto S., Takahashi T., Ito M., Matozaki S., Nakagawa T. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with cyclosporin A. Cancel 1992; 69: 2567–2570
- Siegert W., Agthe A., Griesser H., Schwerdtfeger R., Brittinger G., Engelhard M., Kuse R., Tiemann M., Lennert K., Huhn D., The Kiel Lymphoma Study Group. Treatment of angioimmunoblastic lymphadenopathy (A1LD)‐type T‐cell lymphoma using prednisone with or without the COPBLAMAMVP‐16 regimen. A multicenter study. Annals of Internal Medicine 1992; 117: 366370
- Sallah A. S., Bernard S. Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia using 2‐hloro‐deoxyadenosine. Annals of Hematology. 1996; 73: 295–296
- Ong S. T., Koeppen H., Larson R. A., Olopade O. I. Successful treatment of angioimmunioblastic lymphadenopathy with dysproteinemia with fludarabine. Blood 1996; 88: 2354–2355
- Yamamura M., Honda M., Yamada Y., Itoyama T., Sohda H., Yubashi T., Momita S., Kamihira S., Ohmoto Y., Tomonaga M. Increased levels of interleukin‐6 (IL‐6) in serum and spontaneous in vitro production of IL‐6 by lymph node mononuclear cells of patients with angio‐immu‐noblastic lymphadenopathy with dysproteinemia (AILD), and clinical effectiveness of cyclosporin A. Leukemia 1996; 10: 1504–1508
- Keating M. J., O'Brien S., Lemer S., Koller C., Beran M., Robertson L. E., Freirich E. J., Estey E., Kantarjian H. Long‐term follow‐up of patients with chronic lym‐phocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165–1171
- Hiddemann W., Unterhalt M., Pott C., Wormann B., Sand‐ford D., Freund M., Engert A., Gassmann W., Holtkamp W., Seufert J. Fludarabine single‐agent therapy for relapsed low‐grade non‐Hodgkin's lymphomas: a phase II study of the German Low‐Grade Non‐Hodgkin's Lymphoma Study Group. Seminars in Oncology 1993; 20: 28–31
- Witzig T. E., Weitz J. J., Lundberg J. H., Tefferi A. Treatment of refractory T‐cell chronic lymphocytic leukemia with purine nucleoside analogues. Leukemia and Lymphoma 1994; 14: 137–139